Abstract
Pazopanib and axitinib are both U.S. Food and Drug Administration approved ATP-competitive inhibitors of the vascular endothelial growth factor receptor. Pazopanib and axitinib have been shown to be effective and tolerable treatment options for patients with metastatic renal cell cancer and therefore have enlarged the armamentarium for this disease. This concise drug review discusses the clinical benefits, clinical use, mechanism of action, bioanalysis, pharmacokinetics, pharmacogenetics, pharmacodynamics, drug resistance, toxicity, and patient instructions and recommendations for supportive care for these two drugs.
Original language | Undefined/Unknown |
---|---|
Pages (from-to) | 1081-9 |
Number of pages | 9 |
Journal | Oncologist |
Volume | 17 |
Issue number | 8 |
Publication status | Published - 2012 |